Valeurs seuils pour le rapport coût-efficacité en soins de santé - KCE
Valeurs seuils pour le rapport coût-efficacité en soins de santé - KCE
Valeurs seuils pour le rapport coût-efficacité en soins de santé - KCE
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>KCE</strong> reports 100 ICER Thresholds 3<br />
GLOSSARY<br />
Beveridge-type health care system Taxation-fun<strong>de</strong>d public health service system (named after<br />
William Beveridge, 20 th c<strong>en</strong>tury British economist and politician).<br />
Bismarck-type health care system Health care system where public and private provi<strong>de</strong>rs are<br />
reimbursed by compulsory health insurance funds (named after<br />
Otto von Bismarck, 19 th c<strong>en</strong>tury German chancellor).<br />
Confid<strong>en</strong>ce interval (CI) Statistical concept. Interval likely to inclu<strong>de</strong> the estimated<br />
parameter with a giv<strong>en</strong> confid<strong>en</strong>ce <strong>le</strong>vel, for examp<strong>le</strong> 95% CI.<br />
Results are pres<strong>en</strong>ted as a point estimate surroun<strong>de</strong>d by its<br />
confid<strong>en</strong>ce interval.<br />
Cost-b<strong>en</strong>efit analysis Type of economic evaluation in which all costs incurred and<br />
resulting b<strong>en</strong>efits of an interv<strong>en</strong>tion are expressed in monetary<br />
units (e.g. €) and a net monetary gain/loss or cost-b<strong>en</strong>efit ratio is<br />
computed.<br />
Cost-consequ<strong>en</strong>ce analysis A variant of cost-effectiv<strong>en</strong>ess analysis in which the compon<strong>en</strong>ts<br />
of increm<strong>en</strong>tal costs and consequ<strong>en</strong>ces (health outcomes) of<br />
alternative programmes are computed and listed, without<br />
Cost-effectiv<strong>en</strong>ess acceptability<br />
curve<br />
aggregation into a cost-effectiv<strong>en</strong>ess ratio or cost-utility ratio.<br />
Curve repres<strong>en</strong>ting the probability of an interv<strong>en</strong>tion being costeffective<br />
(Y-axis), giv<strong>en</strong> differ<strong>en</strong>t values for the ICER threshold<br />
value (X-axis). The curve ref<strong>le</strong>cts the uncertainty around the<br />
ICER estimate.<br />
Cost-effectiv<strong>en</strong>ess analysis Method of comparing alternative treatm<strong>en</strong>ts in which the costs<br />
and consequ<strong>en</strong>ces of the treatm<strong>en</strong>ts vary. The outcomes of<br />
alternative treatm<strong>en</strong>ts are measured in the same non-monetary<br />
(natural) unit (e.g. life years gained, ev<strong>en</strong>ts avoi<strong>de</strong>d, …).<br />
Cost-minimisation analysis Method of comparing the costs of alternative health<br />
interv<strong>en</strong>tions that are assumed to have an equiva<strong>le</strong>nt effect on<br />
health outcomes.<br />
Cost-utility analysis Special form of cost-effectiv<strong>en</strong>ess analysis in which the costs per<br />
unit of ‘utility’ are calculated. The term is also frequ<strong>en</strong>tly used<br />
for economic evaluations that take the impact of an interv<strong>en</strong>tion<br />
on health-related quality of life into account, irrespective of<br />
whether the outcome measure can be regar<strong>de</strong>d as a true utility<br />
measure in its theoretical economic s<strong>en</strong>se. The most commonly<br />
used outcome measure in cost-utility analyses is the qualityadjusted<br />
life year (QALY).<br />
Credibility interval Confid<strong>en</strong>ce interval around a cost-effectiv<strong>en</strong>ess ratio resulting<br />
from an economic mo<strong>de</strong>l. In contrast to statistical confid<strong>en</strong>ce<br />
intervals, the values within a credibility interval are not actually<br />
observed but result from a mathematical mo<strong>de</strong>l, making<br />
assumptions about the relationships and distributions of input<br />
variab<strong>le</strong>s.<br />
Discounting Economic concept to hand<strong>le</strong> time-prefer<strong>en</strong>ce, using a method of<br />
calculation by which costs and b<strong>en</strong>efits occurring at differ<strong>en</strong>t<br />
mom<strong>en</strong>ts in time can be compared. Discounting converts the<br />
value of future costs and b<strong>en</strong>efits into their pres<strong>en</strong>t value to<br />
account for positive time prefer<strong>en</strong>ces for b<strong>en</strong>efits (prefer<strong>en</strong>ce<br />
for curr<strong>en</strong>t b<strong>en</strong>efits as compared to future b<strong>en</strong>efits) and negative<br />
time prefer<strong>en</strong>ces for costs (prefer<strong>en</strong>ce for future costs as<br />
compared to curr<strong>en</strong>t costs).<br />
Economic evaluation Comparative analysis of alternative courses of action in terms of<br />
Effectiv<strong>en</strong>ess<br />
(effectiviteit/doeltreff<strong>en</strong>dheid;<br />
<strong>efficacité</strong> réel<strong>le</strong>/<strong>efficacité</strong> pratique<br />
Efficacy (efficaciteit/werkzaamheid;<br />
<strong>efficacité</strong> théorique/<strong>efficacité</strong><br />
expérim<strong>en</strong>ta<strong>le</strong>/<strong>efficacité</strong><br />
both their costs and consequ<strong>en</strong>ces.<br />
The ext<strong>en</strong>t to which health interv<strong>en</strong>tions achieve health<br />
improvem<strong>en</strong>ts in real-life settings.<br />
The ext<strong>en</strong>t to which health interv<strong>en</strong>tions achieve health<br />
improvem<strong>en</strong>ts un<strong>de</strong>r i<strong>de</strong>al control<strong>le</strong>d conditions (as for examp<strong>le</strong><br />
in randomised control<strong>le</strong>d trials)